



The 14th Annual Congress on Controversies in
Ophthalmology: COPHy 2023
March 24-25, 2023, Lisbon, Portugal

Updated March 5, 2023

FRIDAY, MARCH 24, 2023	
07:30-08:30	Pre-Congress Industry Sponsored Breakfast Symposium
08:30-10:00	OPENING SESSION Big Controversies in Retina in 2023 HALL A
Chairs:	<u>Baruch Kuppermann</u> , USA; <u>Anat Loewenstein</u> , Israel; <u>Rufino Silva</u> , Portugal
08:30-08:40	Opening Remarks <u>Baruch Kuppermann</u> , USA; <u>Anat Loewenstein</u> , Israel; <u>Rufino Silva</u> , Portugal
08:40-09:00	<i>Keynote Lecture</i>
08:40-08:55	Translating discoveries at the molecular level to new therapies for eye diseases: The Institute of Molecular and Clinical Ophthalmology Basel (IOB) <u>Hendrik Scholl</u> , Switzerland
08:55-09:00	Q&A
09:00-09:30	Debate 1: In 5 years we will abandon clinical examination for telemedicine and AI assisted decisions
09:00-09:10	Yes: <u>Ursula Schmidt-Erfurth</u> , Austria
09:10-09:20	No: <u>Manuel Falcão</u> , Portugal
09:20-09:30	Discussion
09:30-10:00	Debate 2: Complement inhibition is a game changer in the management of patients with geographic atrophy
09:30-09:40	Yes: <u>Peter K. Kaiser</u> , USA
09:40-09:50	No: <u>Ursula Schmidt-Erfurth</u> , Austria
09:50-10:00	Discussion
10:00-10:30	Visit Exhibition, Posters & Coffee and Refreshment Break



The 14th Annual Congress on Controversies in
Ophthalmology: COPHy 2023
March 24-25, 2023, Lisbon, Portugal

FRIDAY, MARCH 24, 2023

10:30-12:00	MEDICAL RETINA 1 Neovascular (“Wet”) AMD Management	HALL A
Chairs:	<u>Rufino Silva</u> , Portugal; <u>Antonio Campos</u> , Portugal	
10:30-11:00	Debate 1: Durability associated with multi target therapies is superior to anti-VEGF mono-target therapy in AMD	
10:30-10:40	Yes: <u>Anat Loewenstein</u> , Israel	
10:40-10:50	No: <u>Antonio Campos</u> , Portugal	
10:50-11:00	Discussion	
11:00-11:30	Debate 2: Higher doses of existing intravitreal drugs can be beneficial in the management of nAMD	
11:00-11:10	Yes: <u>Peter K. Kaiser</u> , USA	
11:10-11:20	No: <u>Michaela Goldstein</u> , Israel	
11:20-11:30	Discussion	
11:30-12:00	Debate 3: Presence of macular neovascularization on OCTA is predictive of subsequent exudation	
11:30-11:40	Yes: <u>Angela Carneiro</u> , Portugal	
11:40-11:50	No: <u>Stephan Michels</u> , Switzerland	
11:50-12:00	Discussion	
12:15-13:15	Industry Sponsored Luncheon Symposium (<i>Lunch boxes served 12:00-12:15</i>)	
13:15-13:45	Visit Exhibition, Posters & Dessert Break	



The 14th Annual Congress on Controversies in
Ophthalmology: COPHy 2023
March 24-25, 2023, Lisbon, Portugal

FRIDAY, MARCH 24, 2023

13:45-15:15	SURGICAL RETINA 1 Controversial Approaches to Common Surgical Questions	HALL A
Chairs:	<u>William F. Mieler</u> , USA; <u>Stanislao Rizzo</u> , Italy, <u>Stratos Gotzaris</u> , Greece	
13:45-14:15	Debate 1: Vitrectomy is safe and beneficial in the management of significant vitreous opacities	
13:45-13:55	Yes: <u>Francesco Boscia</u> , Italy	
13:55-14:05	No: <u>William F. Mieler</u> , USA	
14:05-14:15	Discussion	
14:15-14:45	Debate 2: In epiretinal membrane surgery, removal of the ILM is essential	
14:15-14:25	Yes: <u>João Figueira</u> , Portugal	
14:25-14:35	No: <u>Francesco Boscia</u> , Italy	
14:35-14:45	Discussion	
14:45-15:15	Debate 3: The preferred procedure for a large refractory macular hole is autologous retinal transplantation?	
14:45-14:55	Yes: <u>Stanislao Rizzo</u> , Italy	
14:55-15:05	No: <u>José Maria Ruiz-Moreno</u> , Spain	
15:05-15:15	Discussion	



The 14th Annual Congress on Controversies in
Ophthalmology: COPHy 2023
March 24-25, 2023, Lisbon, Portugal

FRIDAY, MARCH 24, 2023

15:15-16:15	VISION ACADEMY IN RETINA 2023 Controversies in the Management of Intravitreal Therapy for Retinal Diseases	HALL A
Chairs:	<u>Baruch Kuppermann</u> , USA; <u>Anat Loewenstein</u> , Israel	
15:15-15:20	Welcome and Introductions: <u>Anat Loewenstein</u> , Israel	
15:20-15:35	Debate 1: Optimal application of anti-VEGFs: Do we need to reconsider our treatment paradigms?	
15:20-15:30	<u>Bora Eldem</u> , Turkey & <u>Robert Finger</u> , Germany	
15:30-15:35	Presentation of Viewpoint: <u>Anat Loewenstein</u> , Israel	
15:35-15:50	Debate 2: Should we be concerned about IOP spikes after IVTs?	
15:35-15:45	<u>Polona Jaki Mekjavic</u> , Poland; <u>Sobha Sivaprasad</u> , UK	
15:45-15:50	Presentation of Viewpoint: <u>Anat Loewenstein</u> , Israel	
15:50-16:10	Panel discussion / Audience Q&A	
16:10-16:15	Summary and Close: <u>Anat Loewenstein</u> , Israel	
16:15-17:15	Industry Sponsored Symposium	
17:15	"Happy Hour" Cocktail	
End of Day		



The 14th Annual Congress on Controversies in
Ophthalmology: COPHy 2023
March 24-25, 2023, Lisbon, Portugal

SATURDAY, MARCH 25, 2023		
	HALL A	HALL B
08:30-10:00	MEDICAL RETINA 2 Diabetic Macular Edema (DME) and Proliferative Diabetic Retinopathy	NEURO-OPHTHALMOLOGY 1 The Afferent Pathway
Chairs:	Paolo Lanzetta , Italy; José Cunha-Vaz , Portugal; Francesco Bandello , Italy	Andrew G. Lee , USA; TBA
08:30-09:00	Debate 1: Can biomarkers be used to determine if steroids vs anti-VEGF agents are more appropriate to treat DME?	Debate 1: Should all patients with thyroid eye disease be offered teprotumumab?
08:30-08:40	Yes: Lilianne Duarte , Portugal	Yes: Pedro Fonseca , Portugal
08:40-08:50	No: Sobha Sivaprasad , UK	No: Andrew G. Lee , USA
08:50-09:00	Discussion	Discussion
09:00-09:30	Debate 2: Is treatment of NPDR with pharmacotherapy warranted at this time?	Debate 2: Should patients with giant cell arteritis be offered tocilizumab?
09:00-09:10	Yes: Sobha Sivaprasad , UK	Yes: John Chen , USA
09:10-09:20	No: José Cunha-Vaz , Portugal	No: Susan Mollan , UK
09:20-09:30	Discussion	Discussion
09:30-10:00	Debate 3: Multi target therapies is superior to anti-VEGF mono-target therapy in DME	Case Presentations
09:30-09:40	Yes: Lilianne Duarte , Portugal	Moderator: John Chen , USA
09:40-09:50	No: Patricia Udaondo , Spain	Panelists: <i>All Speakers</i>
09:50-10:00	Discussion	Andrew G. Lee , USA; Pedro Fonseca , Portugal; Susan Mollan , UK
10:00-10:30	Visit Exhibition, Posters & Coffee and Refreshment Break	



The 14th Annual Congress on Controversies in
Ophthalmology: COPHy 2023
March 24-25, 2023, Lisbon, Portugal

SATURDAY, MARCH 25, 2023

	HALL A	HALL B
10:30-12:00	MEDICAL RETINA 3 AMD and Hereditary Retinal Degeneration Topics	UVEITIS 1
Chairs:	<u>Hendrik Scholl</u> , Switzerland; <u>Angela Carneiro</u> , Portugal; <u>Marco Dutra Medeiros</u> , Portugal	<u>Bahram Bodaghi</u> , France; <u>Zohar Habot-Wilner</u> , Israel
10:30-11:00	Debate 1: Retinal implant is still a future option for patients with hereditary retinal degeneration	Debate 1: Intravitreal corticosteroids for the treatment of uveitic macular edema is better (or similar) than systemic treatment
10:30-10:40	Yes: <u>William F. Mieler</u> , USA	Yes: <u>Aniruddha Agarwal</u> , UAE
10:40-10:50	No: <u>Hendrik Scholl</u> , Switzerland	No: <u>Sarah Touhami</u> , France
10:50-11:00	Discussion	Discussion
11:00-11:30	Debate 2: Home monitoring will be an important management option for our patients with AMD	Debate 2: : Vitrectomy should be performed in patients with ARN syndrome
11:00-11:10	Yes: <u>Rufino Silva</u> , Portugal	Yes: <u>Sarah Touhami</u> , France
11:10-11:20	No: <u>Robert Finger</u> , Germany	No: <u>Luis Figueira</u> , Portugal
11:20-11:30	Discussion	Discussion
11:30-12:00	Debate 3: Suprachoroidal injection of a viral vector expressing an anti-VEGF protein is a viable treatment option for the management of retinal disease	Debate 3: Systemic antibiotic treatment is mandatory for ocular toxoplasmosis
11:30-11:40	Yes: <u>Marco Dutra Medeiros</u> , Portugal	Yes: <u>Aniruddha Agarwal</u> , UAE
11:40-11:50	No: <u>William F. Mieler</u> , USA	No: <u>Zohar Habot-Wilner</u> , Israel
11:50-12:00	Discussion	Discussion
12:15-13:15	Industry-Sponsored Luncheon Symposium (Lunch boxes served 12:00-12:15)	
13:30-14:30	Industry-Sponsored Dessert Box Symposium (Dessert boxes served 13:15-13:30)	
14:30-15:00	Visit Exhibition & Posters	



The 14th Annual Congress on Controversies in
Ophthalmology: COPHy 2023
March 24-25, 2023, Lisbon, Portugal

SATURDAY, MARCH 25, 2023

	HALL A	HALL B
15:00-16:30	SURGICAL RETINA 2 Controversies in the Utilization of Cutting Edge Vitreoretinal Surgical Technology	NEURO-OPHTHALMOLOGY 2 The Efferent Pathway and Systemic Disorders
Chairs:	<u>João Figueira</u> , Portugal; <u>José Maria Ruiz-Moreno</u> , Spain	<u>Andrew G. Lee</u> , USA
15:00-15:30	Debate 1: Digital, heads up imaging in the operating room has led to improvement in surgical outcomes	Debate 1: Patients with NMO be offered eculizumab?
15:00-15:10	Yes: <u>Angelina Meireles</u> , Portugal	Yes: <u>John Chen</u> , USA
15:10-15:20	No: <u>José Maria Ruiz-Moreno</u> , Spain	No: <u>Susan Mollan</u> , UK
15:20-15:30	Discussion	Discussion
15:30-16:00	Debate 2: Surgical intraoperative OCT is practical in VR surgery	Debate 2: All patients with optic neuritis should have both NMO and MOG testing?
15:30-15:40	Yes: <u>Carlos Marques Neves</u> , Portugal	Yes: <u>Pedro Fonseca</u> , Portugal
15:40-15:50	No: <u>Angelina Meireles</u> , Portugal	No: <u>Andrew G. Lee</u> , USA
15:50-16:00	Discussion	Discussion
16:00-16:30	Debate 3: Early surgery in myopic maculopathy versus delayed surgery	Case Presentations
16:00-16:10	Yes: <u>Jorge Ruiz-Medrano</u> , Spain	Moderator: <u>John Chen</u> , USA
16:10-16:20	No: <u>Stratos Gotzaridis</u> , Greece	Panelists: <i>All Speakers</i>
16:20-16:30	Discussion	<u>Andrew G. Lee</u> , USA; <u>Susan Mollan</u> , UK; <u>Pedro Fonseca</u> , Portugal



The 14th Annual Congress on Controversies in
Ophthalmology: COPHy 2023
March 24-25, 2023, Lisbon, Portugal

SATURDAY, MARCH 25, 2023

	HALL A	HALL B
16:30-18:00	MEDICAL RETINA 4 New Treatment Strategies	UVEITIS 2
Chairs:	<u>Rufino Silva</u> , Portugal; <u>Patricia Udaondo</u> , Spain	<u>Bahram Bodaghi</u> , France; <u>Zohar Habot-Wilner</u> , Israel
16:30-17:00	Debate 1: Biosimilars will become the primary treatment option for retinal diseases	Debate 1: Vogt Koyanagi Harada: Immunomodulatory treatment should be started at the first manifestation of VKH alongside with systemic corticosteroids
16:30-16:40	Yes: <u>Ashish Sharma</u> , India	Yes: <u>Ines Leal</u> , Portugal
16:40-16:50	No: <u>Paolo Lanzetta</u> , Italy	No: <u>Bahram Bodaghi</u> , France
16:50-17:00	Discussion	Discussion
17:00-16:30	Debate 2: Continuous delivery with the Port Delivery System will be is an important treatment option for patients with nAMD	Debate 2: Cataract surgery in JIA-uveitis: leaving the child aphakic
17:00-17:10	Yes: <u>Rita Flores</u> , Portugal	Yes: <u>Ines Leal</u> , Portugal
17:10-17:20	No: <u>Patricia Udaondo</u> , Spain	No: <u>Bahram Bodaghi</u> , France
17:20-17:30	Discussion	Discussion
17:30-18:00	Debate 3: Sub-retinal viral vector gene therapy delivery of anti-VEGF is a viable management option for the management of retinal disease	Debate 3: Intraocular corticosteroids may be used for infectious uveitis
17:30-17:40	Yes: <u>João Figueira</u> , Portugal	Yes: <u>Luis Figueira</u> , Portugal
17:40-17:50	No: <u>Paolo Lanzetta</u> , Italy	No: <u>Zohar Habot-Wilner</u> , Israel
17:50-18:00	Discussion	Discussion
End of Congress		